Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Sara Lonardi, MD
Aparna R. Parikh, MD
Alan Venook, MD
Management of HER2-Low MBC Following First-Line Disease Progression
Peter Schmid, FRCP, MD, PhD
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Emerging Treatment Approaches for EBC
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Detecting Recurrent Breast Cancer: The Role of Liquid Biopsies and Molecular Markers
Ben Park, MD, PhD
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01
Jacob Sands, MD
Aaron Lisberg, MD
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Charles Turck, PharmD, BCPS, BCCCP
Thomas Egenod, MD
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial
Alex Spira, MD, PhD, FACP
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
Nicoletta Colombo, MD
Ritu Salani, MD, MBA
Agonists vs Antagonists: Evaluating ADT Efficacy as Monotherapy and Combination Therapy in Hormone-Sensitive Prostate Cancer
Rana McKay, MD
Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer
Susana Campos, MD, MPH
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.